{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016619","form_type":"8-K","ticker":"TCMD","cik":"0001027838","company_name":"TACTILE SYSTEMS TECHNOLOGY INC","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.289554+00:00","generated_at":"2026-06-22T04:57:39.094562+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tactile Medical Q3 revenue up 24% to $65.3M; raises FY2022 guidance","bullets":["Q3 revenue $65.3M (+24% YoY); net loss $2.3M ($0.11/sh) vs loss $3.4M ($0.17) a year ago.","Non-GAAP net income $1.9M vs non-GAAP loss $1.6M; Adjusted EBITDA $7.2M vs $4.1M.","Airway clearance revenue $11.0M (incl. AffloVest); lymphedema revenue up 5%.","Raises FY2022 revenue guidance to $242-245M (16-18% growth) from prior $238-242M.","Gross margin improved to 71.7% from 70.4%; cash $23.4M, debt $49.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016619","json":"https://secwatch.observer/filing/0001558370-22-016619.json","markdown":"https://secwatch.observer/filing/0001558370-22-016619.md","text":"https://secwatch.observer/filing/0001558370-22-016619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1027838/000155837022016619/0001558370-22-016619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1027838/000155837022016619/tcmd-20221107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:57:39.094562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f646fa97095f85d2c2b14694e28388f14e7e9698","claim":"TACTILE SYSTEMS TECHNOLOGY INC reported the third quarter and nine months ended September 30, 2022 results: revenue $65.3 million, net income $2.3 million, EPS $0.11 per diluted share. Guidance raised.","evidence_excerpt":"today reported financial results for the third quarter and nine months ended September 30, 2022. Third Quarter 2022 Summary: ● Total revenue increased 24% year-over-year to $65.3 million, compared to $52.5 million in third quarter 2021. ● Total revenue in third quarter 2022 included $11.0 million of revenue from sales of airway clearance products, which includes","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1027838/000155837022016619/0001558370-22-016619-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter and nine months ended September 30, 2022"},{"label":"Revenue","value":"$65.3 million"},{"label":"Net income","value":"$2.3 million"},{"label":"EPS","value":"$0.11 per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}